Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03146546 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

STUDY00015328: Sepsis Endotypes

StatusEnrolling by Invitation
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 years later Jun 30, 2026 → Jun 30, 2028
See other at-risk trials from Milton S. Hershey Medical Center

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Jun 30, 2026 to Jun 30, 2028
    • Eligibility criteria expanded, about 9 words
    • Secondary endpoints: details revised at 1 of 5 entries
    • Publications: details revised at 7 of 8 entries
  2. 2 versions Re-verified since Dec 5, 2024, no change to tracked fieldsv10-v11
  3. Primary and study completion dates: Jun 30, 2025 to Jun 30, 2026
    • Secondary endpoints: 4 to 5
    • Study description shortened, about 724 words
    v9
  4. Re-verified, no change to tracked fieldsv8
  5. Enrollment target: 40 to 200v7 Show 7 more changesShow less
    • Start date: Jun 1, 2017 to Aug 6, 2020
    • Primary endpoint revised
    • Primary and study completion dates: Jun 1, 2025 to Jun 30, 2025
    • Eligibility criteria expanded, about 14 words
    • Secondary endpoints: 3 to 4
    • Study description expanded, about 621 words
    • Study title shortened, about 5 words
Show 5 earlier versionsHide 5 earlier versions
  1. Primary completion date: Jun 1, 2021 to Jun 1, 2025
    • Study completion date: Jul 1, 2021 to Jun 1, 2025
    v6
  2. Trial status: Recruiting to Enrolling by Invitation
    • Site details revised
    v5
  3. Primary completion date: Jun 1, 2019 to Jun 1, 2021
    • Study completion date: Jul 1, 2019 to Jul 1, 2021
    v4
  4. Primary completion date: Jun 1, 2018 to Jun 1, 2019
    • Study completion date: Jul 1, 2018 to Jul 1, 2019
    v3
  5. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Sep 1, 2017 to Jun 1, 2017
    • Site details revised
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Determine the utility of biomarkers measured in blood and body fluid (stool, saliva, tracheal aspirate) when combined with clinical data, for predicting sepsis phenotypes that are associated with poor clinical outcomes. We hypothesize that resistin is a biomarker which provides critical prognostic information when used in conjunction with standard clinical data, in patients with sepsis and septic shock.
Trial Details
NCT Number NCT03146546
Lead Sponsor Milton S. Hershey Medical Center
Conditions
(from sponsor)		 Sepsis
Related terms Sepsis
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov